Breaking Finance News

JPMorgan Chase & Co. upgraded Acorda Therapeutics Inc (NASDAQ:ACOR) to Overweight in a report released today.

JPMorgan Chase & Co. has upgraded Acorda Therapeutics Inc (NASDAQ:ACOR) to Overweight in a report released on 11/30/2016.

Previously on Wednesday January 06, 2016, Aegis Capital reported about Acorda Therapeutics Inc (NASDAQ:ACOR) raised the target price from $40.00 to $52.00. At the time, this indicated a possible upside of 0.26%.

Yesterday Acorda Therapeutics Inc (NASDAQ:ACOR) traded 0.48% higher at $20.75. The company’s 50-day moving average is $19.64 and its 200-day moving average is $23.83. The last stock close price is down -12.92% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 274,569 shares of the stock were exchanged, down from an average trading volume of 639,605

See Chart Below

Acorda Therapeutics Inc (NASDAQ:ACOR)

Acorda Therapeutics Inc has a 52 week low of $16.40 and a 52 week high of $43.63 The company’s market cap is currently $0.

In addition to JPMorgan Chase & Co. reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $47.20 with 1 firm rating the stock a strong buy, 3 firms rating the stock a buy, 4 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Acorda Therapeutics Inc (NASDAQ:ACOR)

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *